152 related articles for article (PubMed ID: 29083228)
61. Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling.
Ji X; Meng X; He Q; Xiang X; Shi Y; Zhu X
Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614199
[TBL] [Abstract][Full Text] [Related]
62. Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer.
Wali VB; Patwardhan GA; Pelekanou V; Karn T; Cao J; Ocana A; Yan Q; Nelson B; Hatzis C; Pusztai L
Sci Rep; 2019 Oct; 9(1):14934. PubMed ID: 31624295
[TBL] [Abstract][Full Text] [Related]
63. Novel Peptide CM 7 Targeted c-Met with Antitumor Activity.
Xia C; Wang Y; Liu C; Wang L; Gao X; Li D; Qi W; An R; Xu H
Molecules; 2020 Jan; 25(3):. PubMed ID: 31973231
[TBL] [Abstract][Full Text] [Related]
64. Discovery and optimization of withangulatin A derivatives as novel glutaminase 1 inhibitors for the treatment of triple-negative breast cancer.
Zhou WX; Chen C; Liu XQ; Li Y; Lin YL; Wu XT; Kong LY; Luo JG
Eur J Med Chem; 2021 Jan; 210():112980. PubMed ID: 33176943
[TBL] [Abstract][Full Text] [Related]
65. The clinical and functional significance of c-Met in breast cancer: a review.
Ho-Yen CM; Jones JL; Kermorgant S
Breast Cancer Res; 2015 Apr; 17(1):52. PubMed ID: 25887320
[TBL] [Abstract][Full Text] [Related]
66. Shikonin is a novel and selective IMPDH2 inhibitor that target triple-negative breast cancer.
Wang W; Wu Y; Chen S; Liu X; He J; Wang S; Lu W; Tang Y; Huang J
Phytother Res; 2021 Jan; 35(1):463-476. PubMed ID: 32779300
[TBL] [Abstract][Full Text] [Related]
67. Rutin inhibits human leukemia tumor growth in a murine xenograft model in vivo.
Lin JP; Yang JS; Lin JJ; Lai KC; Lu HF; Ma CY; Sai-Chuen Wu R; Wu KC; Chueh FS; Gibson Wood W; Chung JG
Environ Toxicol; 2012 Aug; 27(8):480-4. PubMed ID: 21254320
[TBL] [Abstract][Full Text] [Related]
68. Antitumor activity of nanoliposomes encapsulating the novobiocin analog 6BrCaQ in a triple-negative breast cancer model in mice.
Sauvage F; Fattal E; Al-Shaer W; Denis S; Brotin E; Denoyelle C; Blanc-Fournier C; Toussaint B; Messaoudi S; Alami M; Barratt G; Vergnaud-Gauduchon J
Cancer Lett; 2018 Sep; 432():103-111. PubMed ID: 29883750
[TBL] [Abstract][Full Text] [Related]
69. Exploring the therapeutic potential of rutin through investigating its inhibitory mechanism on lactate dehydrogenase: Multi-spectral methods and computer simulation.
Ding P; Yang K; Wang H; Kuang L; Gao L; Luo J; Tuo X
Bioorg Chem; 2024 Aug; 149():107503. PubMed ID: 38823312
[TBL] [Abstract][Full Text] [Related]
70. Novel Chrysin-De-Allyl PAC-1 Hybrid Analogues as Anticancer Compounds: Design, Synthesis, and Biological Evaluation.
Al-Oudat BA; Ramapuram H; Malla S; Audat SA; Hussein N; Len JM; Kumari S; Bedi MF; Ashby CR; Tiwari AK
Molecules; 2020 Jul; 25(13):. PubMed ID: 32635530
[TBL] [Abstract][Full Text] [Related]
71. Inhibition of Glutamine Cellular Uptake Contributes to the Cytotoxic Effect of Xanthohumol in Triple-Negative Breast Cancer Cells.
Carmo F; Silva C; Martel F
Nutr Cancer; 2022; 74(9):3413-3430. PubMed ID: 35594207
[TBL] [Abstract][Full Text] [Related]
72. Novel c-Met inhibitory olive secoiridoid semisynthetic analogs for the control of invasive breast cancer.
Mohyeldin MM; Busnena BA; Akl MR; Dragoi AM; Cardelli JA; El Sayed KA
Eur J Med Chem; 2016 Aug; 118():299-315. PubMed ID: 27258622
[TBL] [Abstract][Full Text] [Related]
73. The anticancer potential of the dietary polyphenol rutin: Current status, challenges, and perspectives.
Farha AK; Gan RY; Li HB; Wu DT; Atanasov AG; Gul K; Zhang JR; Yang QQ; Corke H
Crit Rev Food Sci Nutr; 2022; 62(3):832-859. PubMed ID: 33054344
[TBL] [Abstract][Full Text] [Related]
74. Discovery of TGFBR1 (ALK5) as a potential drug target of quercetin glycoside derivatives (QGDs) by reverse molecular docking and molecular dynamics simulation.
Xu J; Zhang S; Wu T; Fang X; Zhao L
Biophys Chem; 2022 Feb; 281():106731. PubMed ID: 34864228
[TBL] [Abstract][Full Text] [Related]
75. Rutin: A Flavonoid as an Effective Sensitizer for Anticancer Therapy; Insights into Multifaceted Mechanisms and Applicability for Combination Therapy.
Satari A; Ghasemi S; Habtemariam S; Asgharian S; Lorigooini Z
Evid Based Complement Alternat Med; 2021; 2021():9913179. PubMed ID: 34484407
[TBL] [Abstract][Full Text] [Related]
76. Rutin (Bioflavonoid) as Cell Signaling Pathway Modulator: Prospects in Treatment and Chemoprevention.
Pandey P; Khan F; Qari HA; Oves M
Pharmaceuticals (Basel); 2021 Oct; 14(11):. PubMed ID: 34832851
[TBL] [Abstract][Full Text] [Related]
77. Discovery of Orphan Olfactory Receptor 6M1 as a New Anticancer Target in MCF-7 Cells by a Combination of Surface Plasmon Resonance-Based and Cell-Based Systems.
Choi YR; Shim J; Park JH; Kim YS; Kim MJ
Sensors (Basel); 2021 May; 21(10):. PubMed ID: 34065710
[TBL] [Abstract][Full Text] [Related]
78. The Pharmacological Potential of Rutin.
Ganeshpurkar A; Saluja AK
Saudi Pharm J; 2017 Feb; 25(2):149-164. PubMed ID: 28344465
[TBL] [Abstract][Full Text] [Related]
79. [Drug safety in gynecology].
Krajnović P; Vranes N
Arch Gynakol; 1975 Nov; 219(1-4):285-7. PubMed ID: 1243338
[No Abstract] [Full Text] [Related]
80. Rutin and orlistat produce antitumor effects via antioxidant and apoptotic actions.
Saleh A; ElFayoumi HM; Youns M; Barakat W
Naunyn Schmiedebergs Arch Pharmacol; 2019 Feb; 392(2):165-175. PubMed ID: 30465055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
